Home Companies Biogen

Biogen

Latest

Genome Editing

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

Businessman Holding Dollar Symbols green and red

Financing

StockWatch: Biogen Stays Flat Despite Positive 128-Week Aduhelm Data

Drug Discovery

Biogen Poised for Pipeline Growth, Samsung Eyes New Drug Expansion after $2.3B Joint Venture Deal

Biogen

Biogen Mulls Tofersen’s Future after Drug Misses Phase III Trial’s Primary Endpoint in ALS

Biogen

FDA Seeks Review of Staff-Biogen Talks Leading to Alzheimer’s Drug Approval

Biogen

Biogen Alzheimer’s Drug Wins Historic Approval, but FDA Requires New Trial

Adeno-associated virus, illustration

Biogen

Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration

Biogen

Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’

Biogen

FDA Accepts Biogen’s BLA for Alzheimer’s Candidate Aducanumab

Biogen

Biogen, Vir to Partner on Manufacturing Antibodies to Treat COVID-19

Biogen

Biogen Shares Surge after Reversal on Alzheimer’s Candidate Aducanumab

Biogen

Fujifilm Diosynth to Expand with $890M Purchase of Biogen’s Danish Biologics...

Biogen

Biogen Replenishes Eye Disease Gene Therapy Pipeline with Planned $877M Nightstar...

Biogen

“Some Hope”: Biogen, Eisai Release Positive Phase II Results for Alzheimer’s...

Biogen

Biogen Raising Minority Stake in Samsung Bioepis in $672M Deal

12 3 Page 1 of 3